BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 2011;29:644-9. [DOI: 10.1016/j.vaccine.2010.11.043] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Tzeng SY, McHugh KJ, Behrens AM, Rose S, Sugarman JL, Ferber S, Langer R, Jaklenec A. Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response. Proc Natl Acad Sci U S A 2018;115:E5269-78. [PMID: 29784798 DOI: 10.1073/pnas.1720970115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
2 Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines 2014;13:221-34. [PMID: 24308581 DOI: 10.1586/14760584.2014.864563] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
3 Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG. Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. J Control Release 2016;244:98-107. [PMID: 27847326 DOI: 10.1016/j.jconrel.2016.11.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
4 Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013;19:1597-608. [PMID: 24309663 DOI: 10.1038/nm.3409] [Cited by in Crossref: 675] [Cited by in F6Publishing: 596] [Article Influence: 84.4] [Reference Citation Analysis]
5 Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine 2015;33:1909-15. [DOI: 10.1016/j.vaccine.2015.02.069] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
6 Grassly NC. The final stages of the global eradication of poliomyelitis. Philos Trans R Soc Lond B Biol Sci 2013;368:20120140. [PMID: 23798688 DOI: 10.1098/rstb.2012.0140] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
7 Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Review of Vaccines 2014;10:635-44. [DOI: 10.1586/erv.11.51] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
8 Fox CB, Huynh C, O’hara MK, Onu A. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine 2013;31:1633-40. [DOI: 10.1016/j.vaccine.2012.10.048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
9 Kraan H, Ploemen I, van de Wijdeven G, Que I, Löwik C, Kersten G, Amorij J. Alternative delivery of a thermostable inactivated polio vaccine. Vaccine 2015;33:2030-7. [DOI: 10.1016/j.vaccine.2015.03.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 2013;31:1298-304. [PMID: 23313617 DOI: 10.1016/j.vaccine.2012.12.076] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
11 Ledet G, Pamujula S, Walker V, Simon S, Graves R, Mandal TK. Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery. Drug Dev Ind Pharm 2014;40:370-9. [PMID: 23600657 DOI: 10.3109/03639045.2012.763137] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
12 Hawken J, Troy SB. Adjuvants and inactivated polio vaccine: a systematic review. Vaccine 2012;30:6971-9. [PMID: 23041122 DOI: 10.1016/j.vaccine.2012.09.059] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
13 Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis 2014;210 Suppl 1:S459-64. [PMID: 25316868 DOI: 10.1093/infdis/jiu128] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
14 Honda-Okubo Y, Baldwin J, Petrovsky N. Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines. Pathogens 2021;10:500. [PMID: 33919442 DOI: 10.3390/pathogens10050500] [Reference Citation Analysis]
15 Dietrich J, Andreasen LV, Andersen P, Agger EM. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. PLoS One 2014;9:e100879. [PMID: 24956110 DOI: 10.1371/journal.pone.0100879] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
16 Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013;12:747-58. [PMID: 23885820 DOI: 10.1586/14760584.2013.811188] [Cited by in Crossref: 88] [Cited by in F6Publishing: 75] [Article Influence: 12.6] [Reference Citation Analysis]
17 Deng J, Cai W, Jin F. A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: Development, characterization, stability and in vivo evaluation. International Journal of Pharmaceutics 2014;468:187-95. [DOI: 10.1016/j.ijpharm.2014.04.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
18 Reed SG, Hsu FC, Carter D, Orr MT. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Curr Opin Immunol 2016;41:85-90. [PMID: 27392183 DOI: 10.1016/j.coi.2016.06.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
19 Tzeng SY, Guarecuco R, McHugh KJ, Rose S, Rosenberg EM, Zeng Y, Langer R, Jaklenec A. Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release. J Control Release 2016;233:101-13. [PMID: 27178811 DOI: 10.1016/j.jconrel.2016.05.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
20 Estívariz CF, Pallansch MA, Anand A, Wassilak SG, Sutter RW, Wenger JD, Orenstein WA. Poliovirus vaccination options for achieving eradication and securing the endgame. Current Opinion in Virology 2013;3:309-15. [DOI: 10.1016/j.coviro.2013.05.007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
21 Baicus A. History of polio vaccination. World J Virol 2012;1:108-14. [PMID: 24175215 DOI: 10.5501/wjv.v1.i4.108] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
22 Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clin Transl Immunology 2015;4:e35. [PMID: 26175894 DOI: 10.1038/cti.2015.6] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 15.0] [Reference Citation Analysis]
23 Andreasen LV, Hansen LB, Andersen P, Agger EM, Dietrich J. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats. Vaccine 2015;33:1873-9. [DOI: 10.1016/j.vaccine.2015.02.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
24 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]